Publications by authors named "Rogier Mous"

Claim this Profile
L
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.
Carsten U Niemann, Julie Dubois, Kazem Nasserinejad, Caspar da Cunha-Bang, Sabina Kersting, Rogier Mous

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP.
Marcel Nijland, Djamila E Issa, Johanna A A Bult, Dries Deeren, Gerjo A Velders, Rogier Mous

Blood Adv· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA.
Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A A Bult, Rogier Mous

J Hematol Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients.
A Vera de Jonge, Erik van Werkhoven, Avinash G Dinmohamed, Marcel Nijland, Aeilko H Zwinderman, Rogier Mous

Blood Cancer J· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematologic malignancies following immune checkpoint inhibition for solid tumors.
Mick J M van Eijs, Lotte E van der Wagen, Rogier Mous, Roos J Leguit, Lisette van de Corput

Cancer Immunol Immunother· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.
Doreen G Te Raa, Lina van der Straten, Michel van Gelder, Sabina Kersting, Mark-David Levin, Rogier Mous

Leuk Lymphoma· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Arnon P Kater, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Rogier Mous

Lancet Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological and Clinical Implications of Gene-Expression Profiling in Diffuse Large B-Cell Lymphoma: A Proposal for a Targeted BLYM-777 Consortium Panel as Part of a Multilayered Analytical Approach.
Fleur A de Groot, Ruben A L de Groen, Anke van den Berg, Patty M Jansen, King H Lam, Rogier Mous

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia.
Eytan M Stein, Daniel J DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Rogier Mous

Clin Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Martin Hutchings, Rogier Mous, Michael Roost Clausen, Peter Johnson, Kim M Linton

Lancet· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study.
Mirian Brink, Xaver U Kahle, Joost S P Vermaat, Josee M Zijlstra, Martine Chamuleau, Rogier Mous

Blood Adv· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
Carsten U Niemann, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Rogier Mous

Blood· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Rebecka Svanberg, Sisse Rye Ostrowski, Kazem Nasserinejad, Sabina Kersting, Johan A Dobber, Rogier Mous

Leuk Lymphoma· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Martine E D Chamuleau, Coreline N Burggraaff, Marcel Nijland, Katerina Bakunina, Rogier Mous

Haematologica· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.
Ana Rio-Machin, Tom Vulliamy, Nele Hug, Amanda Walne, Kiran Tawana, Rogier Mous

Nat Commun· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Rosa Ruchlemer, Ronen Ben-Ami, Maskit Bar-Meir, Jennifer R Brown, Marion Malphettes, Rogier Mous

Mycoses· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients.
Rimke Oostvogels, Margot Jak, Reinier Raymakers, Rogier Mous, Monique C Minnema

Br J Haematol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands.
Sabina Kersting, Suzanne I M Neppelenbroek, Hein P J Visser, Michel van Gelder, Mark-David Levin, Rogier Mous

Clin Lymphoma Myeloma Leuk· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(89) Zr-rituximab PET/CT to detect neurolymphomatosis.
Antoinette de Jong, Rogier Mous, Guus A M S van Dongen, Otto S Hoekstra, Rutger A J Nievelstein

Am J Hematol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia.
Margot Jak, Rogier Mous, Ester B M Remmerswaal, René Spijker, Annelieke Jaspers

Leuk Lymphoma· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands.
Rogier Mous, Philip Savage, Eric Eldering, Peter Teeling, Marinus Hj van Oers

Leuk Lymphoma· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VCAM-1-mediated Rac signaling controls endothelial cell-cell contacts and leukocyte transmigration.
Sandra van Wetering, Nadia van den Berk, Jaap D van Buul, Frederik P J Mul, Ingrid Lommerse, Rogier Mous

Am J Physiol Cell Physiol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis